RiMO-401 / Coordination Pharma - LARVOL DELTA

Phase I Study of RiMO-401 With Radiation in Advanced Tumors (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Coordination Pharmaceuticals, Inc. | N=24 ➔ 5 | Trial completion date: Jul 2026 ➔ Jun 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2026 ➔ Jun 2025; slow enrollment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Solid Tumor

Phase I Study of RiMO-401 With Radiation in Advanced Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Coordination Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Coordination Pharmaceuticals, Inc.

Metastases • New P1 trial • Oncology • Solid Tumor